There are several excellent companies that dabble in two very different markets. Dr Mike Tubbs highlights the ones worth considering now.
Articles written by Dr Mike Tubbs
We have only just started getting to grips with the vast life-saving potential of stem cells, the basic building blocks of the body. Dr Mike Tubbs explores recent breakthroughs and assesses the state of the market.
Move over, Germany and Sweden. There are several world-class UK engineers in profitable niches supplying a vast array of industries with vital equipment. Dr Mike Tubbs picks his favourites.
This Swedish engineer has been overshadowed by bigger local peers, but is well worth a look
Regeneron, a US biotech company, specialises in treating eye diseases. But it’s far from a one-trick pony.
Companies that are set up and then run by the same person for a long time tend to be lucrative investments. Dr Mike Tubbs explains why, how to find founder-managed firms, and which ones to buy now.
This British mid-cap is a successful global player with plenty of room for expansion, says Dr Mike Tubbs.
Immunotherapy is a burgeoning sector that heralds a breakthrough against the world’s second-most deadly disease. Dr Mike Tubbs explains how investors can benefit too.
Alexion focuses on diseases that affect only a tiny proportion of the population – a lucrative niche.
Illumina, the genome sequencing specialist, is a leader in a thriving market. Long-term investors should buy now, says Mike Tubbs.